186 related articles for article (PubMed ID: 16912309)
1. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.
Gao Y; Whitaker-Dowling P; Watkins SC; Griffin JA; Bergman I
J Virol; 2006 Sep; 80(17):8603-12. PubMed ID: 16912309
[TBL] [Abstract][Full Text] [Related]
2. Preferential targeting of vesicular stomatitis virus to breast cancer cells.
Bergman I; Whitaker-Dowling P; Gao Y; Griffin JA
Virology; 2004 Dec; 330(1):24-33. PubMed ID: 15527831
[TBL] [Abstract][Full Text] [Related]
3. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.
Bergman I; Griffin JA; Gao Y; Whitaker-Dowling P
Int J Cancer; 2007 Jul; 121(2):425-30. PubMed ID: 17354238
[TBL] [Abstract][Full Text] [Related]
4. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
5. Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells.
Bergman I; Whitaker-Dowling P; Gao Y; Griffin JA; Watkins SC
Virology; 2003 Nov; 316(2):337-47. PubMed ID: 14644615
[TBL] [Abstract][Full Text] [Related]
6. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
[TBL] [Abstract][Full Text] [Related]
7. Characterization of pseudotype VSV possessing HCV envelope proteins.
Matsuura Y; Tani H; Suzuki K; Kimura-Someya T; Suzuki R; Aizaki H; Ishii K; Moriishi K; Robison CS; Whitt MA; Miyamura T
Virology; 2001 Aug; 286(2):263-75. PubMed ID: 11485395
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.
Johnson JE; Schnell MJ; Buonocore L; Rose JK
J Virol; 1997 Jul; 71(7):5060-8. PubMed ID: 9188571
[TBL] [Abstract][Full Text] [Related]
9. Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein.
Barsoum J; Brown R; McKee M; Boyce FM
Hum Gene Ther; 1997 Nov; 8(17):2011-8. PubMed ID: 9414250
[TBL] [Abstract][Full Text] [Related]
10. A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion.
Stanifer ML; Cureton DK; Whelan SP
J Virol; 2011 Aug; 85(16):8105-15. PubMed ID: 21680501
[TBL] [Abstract][Full Text] [Related]
11. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.
Foley HD; McGettigan JP; Siler CA; Dietzschold B; Schnell MJ
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14680-5. PubMed ID: 11114165
[TBL] [Abstract][Full Text] [Related]
12. Recombinant replication-restricted VSV as an expression vector for murine cytokines.
Miller MA; Lavine CL; Klas SD; Pfeffer LM; Whitt MA
Protein Expr Purif; 2004 Jan; 33(1):92-103. PubMed ID: 14680966
[TBL] [Abstract][Full Text] [Related]
13. Development of an infectious surrogate hepatitis C virus based on a recombinant vesicular stomatitis virus expressing hepatitis C virus envelope glycoproteins and green fluorescent protein.
Okuma K; Fukagawa K; Tateyama S; Kohma T; Mochida K; Hiyoshi M; Takahama Y; Hamaguchi Y; Hirose K; Buonocore L; Rose JK; Mizuochi T; Hamaguchi I
Jpn J Infect Dis; 2015; 68(3):203-8. PubMed ID: 25672345
[TBL] [Abstract][Full Text] [Related]
14. Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication.
Tamura K; Oue A; Tanaka A; Shimizu N; Takagi H; Kato N; Morikawa A; Hoshino H
Microbes Infect; 2005 Jan; 7(1):29-40. PubMed ID: 15716060
[TBL] [Abstract][Full Text] [Related]
15. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
Majid AM; Ezelle H; Shah S; Barber GN
J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
Fredericksen BL; Whitt MA
Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
[TBL] [Abstract][Full Text] [Related]
17. Evolution of vesicular stomatitis virus in athymic nude mice: mutations associated with natural killer cell selection.
Vandepol SB; Holland JJ
J Gen Virol; 1986 Mar; 67 ( Pt 3)():441-51. PubMed ID: 3005478
[TBL] [Abstract][Full Text] [Related]
18. Overproduction of double-stranded RNA in vesicular stomatitis virus-infected cells activates a constitutive cell-type-specific antiviral response.
Ostertag D; Hoblitzell-Ostertag TM; Perrault J
J Virol; 2007 Jan; 81(2):503-13. PubMed ID: 17065213
[TBL] [Abstract][Full Text] [Related]
19. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.
Buonocore L; Blight KJ; Rice CM; Rose JK
J Virol; 2002 Jul; 76(14):6865-72. PubMed ID: 12072487
[TBL] [Abstract][Full Text] [Related]
20. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.
Kahn JS; Schnell MJ; Buonocore L; Rose JK
Virology; 1999 Feb; 254(1):81-91. PubMed ID: 9927576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
